118 related articles for article (PubMed ID: 25262942)
1. Rational design of inhibitors of the bacterial cell wall synthetic enzyme GlmU using virtual screening and lead-hopping.
Doig P; Boriack-Sjodin PA; Dumas J; Hu J; Itoh K; Johnson K; Kazmirski S; Kinoshita T; Kuroda S; Sato TO; Sugimoto K; Tohyama K; Aoi H; Wakamatsu K; Wang H
Bioorg Med Chem; 2014 Nov; 22(21):6256-69. PubMed ID: 25262942
[TBL] [Abstract][Full Text] [Related]
2. Identification and characterization of novel small molecule inhibitors of the acetyltransferase activity of Escherichia coli N-acetylglucosamine-1-phosphate-uridyltransferase/glucosamine-1-phosphate-acetyltransferase (GlmU).
Sharma R; Rani C; Mehra R; Nargotra A; Chib R; Rajput VS; Kumar S; Singh S; Sharma PR; Khan IA
Appl Microbiol Biotechnol; 2016 Apr; 100(7):3071-85. PubMed ID: 26563552
[TBL] [Abstract][Full Text] [Related]
3. An aminoquinazoline inhibitor of the essential bacterial cell wall synthetic enzyme GlmU has a unique non-protein-kinase-like binding mode.
Larsen NA; Nash TJ; Morningstar M; Shapiro AB; Joubran C; Blackett CJ; Patten AD; Boriack-Sjodin PA; Doig P
Biochem J; 2012 Sep; 446(3):405-13. PubMed ID: 22721802
[TBL] [Abstract][Full Text] [Related]
4. Escherichia coli N-Acetylglucosamine-1-Phosphate-Uridyltransferase/Glucosamine-1-Phosphate-Acetyltransferase (GlmU) Inhibitory Activity of Terreic Acid Isolated from Aspergillus terreus.
Sharma R; Lambu MR; Jamwal U; Rani C; Chib R; Wazir P; Mukherjee D; Chaubey A; Khan IA
J Biomol Screen; 2016 Apr; 21(4):342-53. PubMed ID: 26762501
[TBL] [Abstract][Full Text] [Related]
5. In vitro validation of acetyltransferase activity of GlmU as an antibacterial target in Haemophilus influenzae.
Buurman ET; Andrews B; Gao N; Hu J; Keating TA; Lahiri S; Otterbein LR; Patten AD; Stokes SS; Shapiro AB
J Biol Chem; 2011 Nov; 286(47):40734-42. PubMed ID: 21984832
[TBL] [Abstract][Full Text] [Related]
6. Inhibition studies on Mycobacterium tuberculosis N-acetylglucosamine-1-phosphate uridyltransferase (GlmU).
Tran AT; Wen D; West NP; Baker EN; Britton WJ; Payne RJ
Org Biomol Chem; 2013 Dec; 11(46):8113-26. PubMed ID: 24158720
[TBL] [Abstract][Full Text] [Related]
7. Application of fragment-based screening to the design of inhibitors of Escherichia coli DsbA.
Adams LA; Sharma P; Mohanty B; Ilyichova OV; Mulcair MD; Williams ML; Gleeson EC; Totsika M; Doak BC; Caria S; Rimmer K; Horne J; Shouldice SR; Vazirani M; Headey SJ; Plumb BR; Martin JL; Heras B; Simpson JS; Scanlon MJ
Angew Chem Int Ed Engl; 2015 Feb; 54(7):2179-84. PubMed ID: 25556635
[TBL] [Abstract][Full Text] [Related]
8. Identification and optimization of Escherichia coli GlmU inhibitors: an in silico approach with validation thereof.
Mehra R; Sharma R; Khan IA; Nargotra A
Eur J Med Chem; 2015 Mar; 92():78-90. PubMed ID: 25544688
[TBL] [Abstract][Full Text] [Related]
9. Inhibitors of the acetyltransferase domain of N-acetylglucosamine-1-phosphate-uridylyltransferase/glucosamine-1-phosphate-acetyltransferase (GlmU). Part 2: Optimization of physical properties leading to antibacterial aryl sulfonamides.
Stokes SS; Albert R; Buurman ET; Andrews B; Shapiro AB; Green OM; McKenzie AR; Otterbein LR
Bioorg Med Chem Lett; 2012 Dec; 22(23):7019-23. PubMed ID: 23099094
[TBL] [Abstract][Full Text] [Related]
10. Structure of a small-molecule inhibitor complexed with GlmU from Haemophilus influenzae reveals an allosteric binding site.
Mochalkin I; Lightle S; Narasimhan L; Bornemeier D; Melnick M; Vanderroest S; McDowell L
Protein Sci; 2008 Mar; 17(3):577-82. PubMed ID: 18218712
[TBL] [Abstract][Full Text] [Related]
11. Antibacterial FabH Inhibitors with Mode of Action Validated in Haemophilus influenzae by in Vitro Resistance Mutation Mapping.
McKinney DC; Eyermann CJ; Gu RF; Hu J; Kazmirski SL; Lahiri SD; McKenzie AR; Shapiro AB; Breault G
ACS Infect Dis; 2016 Jul; 2(7):456-64. PubMed ID: 27626097
[TBL] [Abstract][Full Text] [Related]
12. Identification of bacteria-selective threonyl-tRNA synthetase substrate inhibitors by structure-based design.
Teng M; Hilgers MT; Cunningham ML; Borchardt A; Locke JB; Abraham S; Haley G; Kwan BP; Hall C; Hough GW; Shaw KJ; Finn J
J Med Chem; 2013 Feb; 56(4):1748-60. PubMed ID: 23362938
[TBL] [Abstract][Full Text] [Related]
13. Novel lead compound optimization and synthesized based on the target structure of Xanthomonas oryzae pv. oryzae GlmU.
Qi X; Deng W; Gao M; Mao B; Xu S; Chen C; Zhang Q
Pestic Biochem Physiol; 2015 Jul; 122():22-8. PubMed ID: 26071803
[TBL] [Abstract][Full Text] [Related]
14. Design and synthesis of novel cell wall inhibitors of Mycobacterium tuberculosis GlmM and GlmU.
Li Y; Zhou Y; Ma Y; Li X
Carbohydr Res; 2011 Sep; 346(13):1714-20. PubMed ID: 21704310
[TBL] [Abstract][Full Text] [Related]
15. Identification of Mtb GlmU Uridyltransferase Domain Inhibitors by Ligand-Based and Structure-Based Drug Design Approaches.
Singh M; Kempanna P; Bharatham K
Molecules; 2022 Apr; 27(9):. PubMed ID: 35566155
[TBL] [Abstract][Full Text] [Related]
16. High-throughput screening identifies novel inhibitors of the acetyltransferase activity of Escherichia coli GlmU.
Pereira MP; Blanchard JE; Murphy C; Roderick SL; Brown ED
Antimicrob Agents Chemother; 2009 Jun; 53(6):2306-11. PubMed ID: 19349513
[TBL] [Abstract][Full Text] [Related]
17. GlmU Inhibitors as Promising Antibacterial Agents: A Review.
Palathoti N; Azam MA
Mini Rev Med Chem; 2023; 23(3):343-360. PubMed ID: 35980047
[TBL] [Abstract][Full Text] [Related]
18. Identification of a new class of FtsZ inhibitors by structure-based design and in vitro screening.
Chan FY; Sun N; Neves MA; Lam PC; Chung WH; Wong LK; Chow HY; Ma DL; Chan PH; Leung YC; Chan TH; Abagyan R; Wong KY
J Chem Inf Model; 2013 Aug; 53(8):2131-40. PubMed ID: 23848971
[TBL] [Abstract][Full Text] [Related]
19. Design and synthesis of thiazole derivatives as potent FabH inhibitors with antibacterial activity.
Li JR; Li DD; Wang RR; Sun J; Dong JJ; Du QR; Fang F; Zhang WM; Zhu HL
Eur J Med Chem; 2014 Mar; 75():438-47. PubMed ID: 24561667
[TBL] [Abstract][Full Text] [Related]
20. Isoprenoid biosynthesis as a target for antibacterial and antiparasitic drugs: phosphonohydroxamic acids as inhibitors of deoxyxylulose phosphate reducto-isomerase.
Kuntz L; Tritsch D; Grosdemange-Billiard C; Hemmerlin A; Willem A; Bach TJ; Rohmer M
Biochem J; 2005 Feb; 386(Pt 1):127-35. PubMed ID: 15473867
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
